deltatrials
Completed PHASE3 NCT00000937

Study and Treatment of Post Lyme Disease (STOP-LD)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Lyme Disease
Interventions Antibiotics
Updated 5 times since 2017 Last updated: Aug 26, 2010 Completion: Nov 30, 2005

A PHASE3 clinical study on Lyme Disease, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 5 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • Stony Brook, United States